BIO-Europe 2026
Talk Presenting Companies (Theatre B) track
Drug Discovery and Development: YATREX
Mon, Nov 9, 2026 · 3:00–3:15 PM CET Koelnmesse
About this session
YATREX is a Luxembourg biopharmaceutical company developing first-in-class therapeutics for ischemic stroke and reperfusion injury. The company's proprietary portfolio comprises YATRX-111, a novel ASIC1-targeting neuroprotective peptide, YATRX-203, an injectable formulation programme designed to improve neuroprotection in acute stroke, and YATRX-305, a differentiated small molecule programme targeting the same biological pathway.
Speaker
-
CEO & Founder · YATREX
Speaker